CCK and Gastrin Peptides in Human Digestive Diseases: From Gallstones to Gut Cancer
CCK and gastrin-related peptides and their receptors play roles in multiple GI diseases including gallbladder dysfunction, pancreatic disorders, and potentially gastrointestinal cancers.
Quick Facts
What This Study Found
CCK/CCK-A receptor dysfunction is implicated in gallbladder and pancreatic diseases, while gastrin/CCK-B receptor abnormalities may contribute to GI cancer development, positioning these peptide systems as therapeutic targets.
Key Numbers
How They Did This
Review of clinical and experimental evidence for CCK, gastrin, and their receptor roles across GI diseases including biliary, pancreatic, and neoplastic conditions.
Why This Research Matters
GI diseases are extremely common. Understanding the peptide signaling dysfunction underlying them could enable targeted treatments that address root causes rather than symptoms.
The Bigger Picture
Gut peptide signaling disorders may underlie many common digestive diseases. Moving from symptom management to peptide-targeted therapy represents a paradigm shift in gastroenterology.
What This Study Doesn't Tell Us
Review with varying evidence levels across diseases. The causal role of peptide receptor dysfunction versus being a consequence of disease is not always clear.
Questions This Raises
- ?Can CCK agonists treat gallbladder motility disorders?
- ?Should gastrin receptor status guide GI cancer screening?
- ?Could CCK receptor modulators prevent certain GI cancers?
Trust & Context
- Key Stat:
- Peptides in GI disease CCK receptor dysfunction drives gallbladder and pancreatic disease, while gastrin receptors may contribute to GI cancer — peptide targets for common conditions
- Evidence Grade:
- Moderate evidence from a review synthesizing clinical and experimental data across multiple GI disease categories.
- Study Age:
- Published in 2002. CCK and gastrin biology in GI disease continues to inform drug development and cancer screening.
- Original Title:
- Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders.
- Published In:
- Pharmacology & toxicology, 91(6), 333-50 (2002)
- Authors:
- Jensen, Robert T(2)
- Database ID:
- RPEP-00736
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Do gut peptides cause digestive diseases?
They can contribute. CCK receptor dysfunction can impair gallbladder emptying (leading to gallstones) and pancreatic function. Gastrin receptor abnormalities may promote certain GI cancers.
Could targeting these peptides treat disease?
Yes. CCK receptor drugs could treat gallbladder motility problems, and gastrin receptor monitoring could guide cancer screening. These are active areas of GI drug development.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00736APA
Jensen, Robert T. (2002). Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders.. Pharmacology & toxicology, 91(6), 333-50.
MLA
Jensen, Robert T. "Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders.." Pharmacology & toxicology, 2002.
RethinkPeptides
RethinkPeptides Research Database. "Involvement of cholecystokinin/gastrin-related peptides and ..." RPEP-00736. Retrieved from https://rethinkpeptides.com/research/jensen-2002-involvement-of-cholecystokiningastrinrelated-peptides
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.